Protocol Deviations

The Protocol Deviations Initiative has developed a toolkit to reduce confusion in definition and a holistic approach to the management of protocol deviations.  These improvements should ultimately lead to improved patient safety, reliability of study data, human subjects protections and data quality. As of January 2023, the Protocol Deviations Initiative is complete. There are no new solutions or updates planned.

Rationale

Survey results from sponsors, sites and IRBs confirmed protocol deviation (PD) management processes are complex, varied and broadly impacted by a wide range of definitions for identification and classification. These differences are associated with process inefficiencies across both sites and sponsors which can hinder rapid identification of important PDs.

In response, the Protocol Deviations Initiative has developed a toolkit to support clarity in definition and a holistic approach to the management of protocol deviations. Improved protocol deviation processes should ultimately lead to improved patient safety, reliability of study data, human subjects protections and data quality and more rapid identification of protocol deviations.

Benefits

Benefits for Patients:

  • Improved identification of important protocol deviations
  • Improved patient safety and human subjects protection
  • Reduction in site burden, potentially improving a study participant’s clinical research experience

Benefits for Sponsors:

  • Reduced burden associated with the interpretation of “important” deviations across all levels of a sponsor’s organization
  • Increased consistency in protocol deviation planning, processing, analysis and reporting mechanisms
  • Focused and efficient risk-based management of protocol deviations which could directly impact patient safety, reliability of study data, human subjects protections and/or data quality

Benefits for Sites:

  • Reduced burden in protocol deviation definitions and associated site processes for management, reducing confusion and increasing speed of identifying important deviations
  • Reduction in overall burden potentially increasing time with patients/study participants

Benefits for Regulatory Authorities:

  • Potential decreased protocol deviations reporting “noise”
  • Potential increased focus on deviations associated with patient safety, reliability of study data, human subjects protections and/or data quality

Available Solutions

For more information and to explore our solutions, visit our Initiative Solutions page.

Related Initiatives

Clinical Content & Reuse

What is Clinical Content & Reuse (CC&R) Click on the Harmonized Model Content, Reuse Capabilities and Clinical Template Suite sections to learn more about CC&R. The Clinical Content & Reuse (CC&R) Initiative enhanced clinical trial processes by providing harmonized structure and proposed model content within clinical trial documents that can be reused throughout the project…

Risk Based Monitoring

The Risk Based Monitoring Initiative was established in 2012 as one of the five initial goals created by TransCelerate to drive efficient and effective solutions into the R&D industry. Clinical trial sites have varying levels of experience and quality, but monitoring approaches are not designed to manage potential differences.

Quality Management System

Through partnerships with Health Authorities and other industry stakeholders, the Quality Management System (QMS) Initiative aims to explore ways to improve quality across the industry.